VILLA GUARDIA (Como), Italy--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) today presented preliminary unaudited top-line results from the Phase 2/3 European pediatric prevention clinical trial of Defibrotide. The results were presented by Selim Corbacioglu, Department of Pediatrics, University of Ulm, Germany, principal investigator of the clinical trial, at the Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) in Göteborg, Sweden.
